Literature DB >> 657528

Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.

R M Weinshilboum, F A Raymond, P A Pazmiño.   

Abstract

A radiochemical micromethod for the determination of thiopurine methyltransferase (TPMT) activity in human red blood cells (RBC) is described. Both 6-mercaptopurine and 6-thioguanine were substrates for the TPMT activity in the human RBC. Apparent Michaelis-Menten (KM) values for 6-mercaptopurine and 6-thioguanine were 3.2 X 10(-4) M and 2.0 X 10(-4) M, respectively. The apparent KM value for S-adenosyl-L-methionine, a co-substrate for the reaction, was 1.7 X 10(-6) M. The pH optimum for the reaction was approximately 7.5. Blood samples from 73 randomly selected adult subjects had a mean activity of 10.2 +/- 2.4 (mean +/- S.D.) units/ml packed red blood cells. The range of activities was from 4.6 to 14.2 units/ml. The results of experiments in which partially purified human kidney TPMT was added to RBC lysates and of experiments in which "low" and "high" activity lysates were mixed gave no indication that individual variations in RBC TPMT activity were due to endogenous inhibitors or activators of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657528     DOI: 10.1016/0009-8981(78)90311-x

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  53 in total

Review 1.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase.

Authors:  M Konstantopoulou; A Belgi; K D Griffiths; J R C Seale; A W Macfarlane
Journal:  BMJ       Date:  2005-02-12

3.  Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation.

Authors:  Liewei Wang; Tien V Nguyen; Richard W McLaughlin; Laura A Sikkink; Marina Ramirez-Alvarado; Richard M Weinshilboum
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

Review 4.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 5.  Pharmacogenetics of cancer therapy: getting personal.

Authors:  E Y Krynetski; W E Evans
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 6.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

7.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.

Authors:  C L Szumlanski; R M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

8.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians.

Authors:  H L Tai; E Y Krynetski; C R Yates; T Loennechen; M Y Fessing; N F Krynetskaia; W E Evans
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

9.  Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.

Authors:  K Schmiegelow; E Forestier; J Kristinsson; S Söderhäll; K Vettenranta; R Weinshilboum; F Wesenberg
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

10.  Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.

Authors:  Qiping Feng; Suda Vannaprasaht; Yi Peng; Susothorn Angsuthum; Yingyos Avihingsanon; Vivien C Yee; Wichittra Tassaneeyakul; Richard M Weinshilboum
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.